BRAIN METASTASES are the most common malignant intracranial neoplasms in adults.[1](#jmri26812-bib-0001){ref-type="ref"} They occur in \~2% of all patients with newly diagnosed invasive solid cancer.[2](#jmri26812-bib-0002){ref-type="ref"} Because of increased surveillance and improved systemic control, the incidence is likely to grow.[1](#jmri26812-bib-0001){ref-type="ref"} Brain metastases are associated with significant morbidity and mortality.[2](#jmri26812-bib-0002){ref-type="ref"} Current care involves stereotactic or whole‐brain radiotherapy and/or surgery, depending on the number, size, and site of metastases, as well as overall systemic disease control and patient\'s performance status.[1](#jmri26812-bib-0001){ref-type="ref"}

An estimated one‐third of brain metastases increase in size after irradiation and the longer the patient survives, the more likely an increase in lesion size will be seen on follow‐up imaging.[3](#jmri26812-bib-0003){ref-type="ref"} This increase in size occurs secondary to blood--brain barrier disruption with accumulation of paramagnetic agents in the extracellular space and is nonspecific[4](#jmri26812-bib-0004){ref-type="ref"}, [5](#jmri26812-bib-0005){ref-type="ref"}: it can represent either treatment‐related changes (pseudoprogression or radionecrosis) or metastatic recurrence. Because of the similar appearance, they are difficult to discriminate on conventional contrast‐enhanced magnetic resonance imaging (MRI).[4](#jmri26812-bib-0004){ref-type="ref"}, [5](#jmri26812-bib-0005){ref-type="ref"}, [6](#jmri26812-bib-0006){ref-type="ref"} Accordingly, lesion measurements on conventional postgadolinium T~1~‐weighted and T~2~‐weighted images are not significantly associated with either treatment‐related changes or metastatic recurrence.[5](#jmri26812-bib-0005){ref-type="ref"} One study suggested that the ratio of the lesion as seen on T~2~‐weighted images to the total enhancing area on postgadolinium T~1~‐weighted images could be useful,[7](#jmri26812-bib-0007){ref-type="ref"} but a later independent study found this so‐called lesion quotient not to be discriminative, with sensitivity and specificity of only 59% and 41%, respectively.[5](#jmri26812-bib-0005){ref-type="ref"} However, early and accurate diagnosis is important, since patients with treatment‐related changes can undergo watchful waiting, whereas patients with metastatic recurrence are potential candidates for surgery or repeated stereotactic radiotherapy.[8](#jmri26812-bib-0008){ref-type="ref"}, [9](#jmri26812-bib-0009){ref-type="ref"} Histopathologic confirmation is the current gold standard,[5](#jmri26812-bib-0005){ref-type="ref"} but biopsy/surgery is invasive, with potential complications such as hemorrhage and infection.[10](#jmri26812-bib-0010){ref-type="ref"} There is therefore a need for a noninvasive tool that can accurately diagnose recurrent brain metastases after radiotherapy. Dynamic susceptibility contrast (DSC) MR perfusion may be used to discriminate treatment‐related changes from metastatic recurrence.[11](#jmri26812-bib-0011){ref-type="ref"}, [12](#jmri26812-bib-0012){ref-type="ref"} DSC MR perfusion uses the first‐pass susceptibility effect of a gadolinium‐based contrast agent within the intravascular compartment.[11](#jmri26812-bib-0011){ref-type="ref"}, [12](#jmri26812-bib-0012){ref-type="ref"} It allows assessment of several hemodynamic imaging variables. The relative cerebral blood volume (rCBV) is the most widely used hemodynamic variable derived from DSC MR perfusion and has been shown to correlate with primary glioma tumor grade and tumor microvascular density.[11](#jmri26812-bib-0011){ref-type="ref"}, [12](#jmri26812-bib-0012){ref-type="ref"} rCBV is generally elevated in viable or recurrent metastases after radiotherapy but not in treatment‐related changes[11](#jmri26812-bib-0011){ref-type="ref"}, [12](#jmri26812-bib-0012){ref-type="ref"} (Figs. [1](#jmri26812-fig-0001){ref-type="fig"}, [2](#jmri26812-fig-0002){ref-type="fig"}). However, the diagnostic performance of DCS MR perfusion is currently not completely clear. Therefore, the purpose of this study was to systematically review the accuracy of DCS MR perfusion in diagnosing recurrent brain metastases after radiotherapy.

![Pseudoprogression of brain metastasis from nonsmall‐cell lung cancer in the right parietotemporal region in a 60‐year‐old woman. Axial contrast‐enhanced T~1~‐weighted image 6 months after stereotactic radiotherapy **(b)** shows increased size of the contrast‐enhancing lesion compared with 3 months before **(a)**. At the CBV map 6 months after stereotactic radiotherapy **(c)** no highly vascularized areas within the contrast‐enhancing lesion are seen, indicative of pseudoprogression. Further follow‐up showed decreasing size of the lesion (MR images not shown), confirming pseudoprogression.](JMRI-51-524-g001){#jmri26812-fig-0001}

![Recurrent metastasis originating from nonsmall‐cell lung cancer in the left occipital lobe in a 69‐year‐old man. Axial contrast‐enhanced T~1~‐weighted image 6 months after stereotactic radiotherapy **(b)** shows increased size of the contrast‐enhancing lesion compared with 3 months before **(a)**. At the CBV map 6 months after stereotactic radiotherapy **(c)** highly vascularized areas within the contrast‐enhancing lesion are seen, indicative of recurrence. The lesion was subsequently resected and histopathological analysis confirmed metastatic recurrence.](JMRI-51-524-g002){#jmri26812-fig-0002}

Materials and Methods {#jmri26812-sec-0013}
=====================

*Data Sources* {#jmri26812-sec-0014}
--------------

A search in MEDLINE and Embase was conducted to find publications on the accuracy of DSC MR perfusion in diagnosing recurrent brain metastases after radiotherapy. The following search terms were used: (brain OR cerebral OR intracranial) AND (metastases OR metastasis OR metastatic) AND (magnetic resonance OR MR imaging OR MRI OR magnetic resonance tomography OR nuclear magnetic resonance OR NMR) AND (perfusion OR dynamic OR susceptibility OR DSC). The search was updated until October 2018. Bibliographies of studies which finally remained after the selection process were screened for potentially suitable references.

*Study Selection* {#jmri26812-sec-0015}
-----------------

Original studies investigating the accuracy of DSC MR perfusion in diagnosing recurrent brain metastases after radiotherapy were eligible for inclusion. Studies involving ≤10 patients with brain metastases were excluded. Studies that only investigated the accuracy of dynamic contrast‐enhanced MR perfusion (relying on T~1~ shortening due to gadolinium‐based contrast) or arterial spin labeling were excluded. Studies that only assessed change in DSC MR perfusion before and after radiotherapy as a predictor of tumor response were also excluded. Studies that provided insufficient data to construct a 2 × 2 contingency table to calculate sensitivity and specificity were also excluded. With the use of the aforementioned selection criteria, titles and abstracts of retrieved studies were reviewed. Full‐text versions of potentially eligible articles were retrieved. Full‐text articles were then reviewed to definitively determine if the study was eligible for inclusion.

*Study Data Extraction* {#jmri26812-sec-0016}
-----------------------

For each included study, principle characteristics (Table [1](#jmri26812-tbl-0001){ref-type="table"}) and true positive, false positive, false negative, and true negative values of DSC MR perfusion in diagnosing recurrent brain metastases were extracted.

###### 

Principal Study Characteristics

<table><thead><tr class="header"><th style="text-align: left;">Study</th><th style="text-align: left;">Publication year, country of origin</th><th style="text-align: left;">Number of patients, age and sex</th><th style="text-align: left;">Primary tumors (%)</th><th style="text-align: left;">DSC MR perfusion parameters‐ Field strength‐ Pulse sequence‐ TR, TE, flip angle‐ Slice thickness‐ FOV, matrix‐ Temporal coverage‐ Gd preload‐ Gd dose‐ Injection rate</th><th style="text-align: left;">Image processing tools</th><th style="text-align: left;">Observers</th><th style="text-align: left;">Diagnostic criteria for recurrence</th><th>Uninterpretable lesions (%)</th><th style="text-align: left;">Reference standard (%)<a href="#jmri26812-note-0002" data-ref-type="fn">a</a></th><th style="text-align: left;">Prevalence of recurrent brain metastases (%)</th></tr></thead><tbody><tr class="odd"><td style="text-align: left;">Wang et al<a href="#jmri26812-bib-0020" data-ref-type="ref">20</a></td><td style="text-align: left;">2018, China</td><td style="text-align: left;">46, median age 61 years (range 30‐80), 22 males</td><td style="text-align: left;"><p>Lung (56.9)</p><p>Breast (17.2)</p><p>Skin (8.6)</p><p>Renal (8.6)</p><p>Colon (8.6)</p></td><td style="text-align: left;"><p>‐ 3 T</p><p>‐ GRE‐EPI</p><p>‐ 1600, 30, 90°</p><p>‐ 4 mm</p><p>‐ 220 × 220, 120 × 120</p><p>‐ 50 measurements</p><p>‐ NR</p><p>‐ 0.2 mmol/kg</p><p>‐ 4.5 ml/s</p></td><td style="text-align: left;">Commercially available software (Syngo.via; Siemens Healthcare)</td><td style="text-align: left;">Two neuroradiologists (both with over 15 years of experience)</td><td style="text-align: left;"><p>‐ CBV lesion &gt;21.8 ml/100g</p><p>‐ rCBV (mean CBV lesion/mean CBV NACWM) &gt;2.12</p></td><td>8.8</td><td style="text-align: left;">Histopathology (9%)<a href="#jmri26812-note-0003" data-ref-type="fn">b</a> or MRI + clinical follow‐up (91%)</td><td style="text-align: left;">56.9</td></tr><tr class="even"><td style="text-align: left;">Knitter et al<a href="#jmri26812-bib-0021" data-ref-type="ref">21</a></td><td style="text-align: left;">2018, USA</td><td style="text-align: left;">29, median age 56 years (interquartile range 48‐64.5), 10 males</td><td style="text-align: left;"><p>Lung (40.6)</p><p>Breast (31.3)</p><p>Melanoma (9.4)</p><p>Renal (6.3)</p><p>Neuroendocrine tumor (3.1)</p></td><td style="text-align: left;"><p>‐ 1.5 T or 3T</p><p>‐ GRE‐EPI</p><p>‐ 1800, 40, 90°</p><p>‐ 5 mm</p><p>‐ 220 × 220, 128 × 128</p><p>‐ 60 measurements</p><p>‐ Yes</p><p>‐ 0.1 mmol/kg</p><p>‐ 5 ml/s</p></td><td style="text-align: left;">Commercially available (Olea Sphere, Olea Medical)</td><td style="text-align: left;">NR</td><td style="text-align: left;">rCBV (mean CBV lesion/mean CBV NACWM) &gt;2.1</td><td>0</td><td style="text-align: left;">MRI follow‐up (100%)</td><td style="text-align: left;">31.3</td></tr><tr class="odd"><td style="text-align: left;">Muto et al<a href="#jmri26812-bib-0022" data-ref-type="ref">22</a></td><td style="text-align: left;">2018, Italy</td><td style="text-align: left;">29 (mean age 53 years (range 33‐79), 11 males</td><td style="text-align: left;"><p>Breast (44.8)</p><p>Lung (41.4)</p><p>Bladder (6.9)</p><p>Colon (6.9)</p></td><td style="text-align: left;"><p>‐ 1.5 T</p><p>‐ GRE‐EPI</p><p>‐ NR</p><p>‐ NR</p><p>‐ NR</p><p>‐ NR</p><p>‐ NR</p><p>‐ 0.1 mmol/kg</p><p>‐ 4.5 ml/s</p></td><td style="text-align: left;">Commercially available (Olea Sphere, Olea Medical)</td><td style="text-align: left;">Two neuroradiologists with 4 and 5 years of experience</td><td style="text-align: left;">rCBV (CBV lesion<a href="#jmri26812-note-0002" data-ref-type="fn">a</a> / NACWM<a href="#jmri26812-note-0002" data-ref-type="fn">a</a>) &gt;2.1</td><td>0</td><td style="text-align: left;">Histopathology (NR)<a href="#jmri26812-note-0003" data-ref-type="fn">b</a> or MRI + clinical follow‐up (NR)</td><td style="text-align: left;">32.1</td></tr><tr class="even"><td style="text-align: left;">Kerkhof al.<a href="#jmri26812-bib-0023" data-ref-type="ref">23</a></td><td style="text-align: left;">2018, The Netherlands</td><td style="text-align: left;">26, median age 66 years (range 40‐84), 12 males</td><td style="text-align: left;"><p>NSCLC (46.2)</p><p>Breast cancer (19.2)</p><p>Other (34.6)</p></td><td style="text-align: left;"><p>‐ 1.5 T</p><p>‐ GRE‐EPI</p><p>‐ 1490, 30, 90°</p><p>‐ 5 mm</p><p>‐ 230 × 230, 128 × 128</p><p>‐ NR</p><p>‐ Yes</p><p>‐ 20 ml Gd</p><p>‐ 4 ml/s</p></td><td style="text-align: left;">Not reported</td><td style="text-align: left;">Two experienced neuroradiologists</td><td style="text-align: left;">Visually highly vascularized areas within the contrast‐enhancing lesion relative to the contralateral hemisphere</td><td>15.5</td><td style="text-align: left;">Histopathology<a href="#jmri26812-note-0004" data-ref-type="fn">c</a> (NR) or MRI follow‐up (NR)</td><td style="text-align: left;">7.7</td></tr><tr class="odd"><td style="text-align: left;">Cicone et al<a href="#jmri26812-bib-0026" data-ref-type="ref">26</a></td><td style="text-align: left;">2015, Italy</td><td style="text-align: left;">42, median age 64 years (range 38‐84), NR</td><td style="text-align: left;"><p>NSCLC (42.0)</p><p>Breast (14.0) Renal (10.0)</p><p>Colon (8.0)</p><p>Melanoma (8.0)</p><p>SCLC (6.0)</p><p>Bladder (4.0)</p><p>Thyroid (4.0)</p><p>Gastric (2.0)</p><p>Cervical (2.0)</p></td><td style="text-align: left;"><p>‐ 1.5 T</p><p>‐ GRE‐EPI</p><p>‐ 1490, 40, 90°</p><p>‐ 5 mm</p><p>‐ 230 × 230, 128 × 128</p><p>‐ 50 measurements in 78 s</p><p>‐ Yes</p><p>‐ 0.1 mmol/kg</p><p>‐ 4 ml/s</p></td><td style="text-align: left;">Commercially available workstation (Leonardo, Siemens Healthcare)</td><td style="text-align: left;">Two experienced readers in consensus</td><td style="text-align: left;">rCBV (maximum CBV lesion/mean CBV NACWM&gt;)2.14</td><td>7.1</td><td style="text-align: left;">Histopathology<a href="#jmri26812-note-0005" data-ref-type="fn">d</a> (22%) or MRI follow‐up (78%)</td><td style="text-align: left;">40.5</td></tr><tr class="even"><td style="text-align: left;">Huang et al<a href="#jmri26812-bib-0028" data-ref-type="ref">28</a></td><td style="text-align: left;">2011, USA</td><td style="text-align: left;">26, NR, NR</td><td style="text-align: left;"><p>Lung (51.5)</p><p>Breast (33.3)</p><p>Esophagus (6.1)</p><p>Melanoma (6.1)</p><p>Renal (3.0)</p></td><td style="text-align: left;"><p>‐ 1.5 T</p><p>‐ GRE‐EPI</p><p>‐ 2480, 98, NR</p><p>‐ 4 mm</p><p>‐ NR (voxel size: 2 × 2 × 4)</p><p>‐ 50 measurements in 125 s</p><p>‐ NR</p><p>‐ 0.1 mmol/kg</p><p>‐ 3 ml/s</p></td><td style="text-align: left;">Commercially available workstation (Pinnacle)</td><td style="text-align: left;">Experienced, board‐certified neuroradiologists</td><td style="text-align: left;">rCBV (maximum CBV lesion/maximum CBV NACWM) &gt;2</td><td>3.6</td><td style="text-align: left;">Histopathology<a href="#jmri26812-note-0004" data-ref-type="fn">c</a> (12%) or MRI + clinical follow‐up (88%)</td><td style="text-align: left;">66.7</td></tr><tr class="odd"><td style="text-align: left;">Mitsuya et al<a href="#jmri26812-bib-0029" data-ref-type="ref">29</a></td><td style="text-align: left;">2010, Japan</td><td style="text-align: left;">27, mean age 59.5 years (range 38‐85), 14 males</td><td style="text-align: left;"><p>Lung (53.6)</p><p>Breast (32.1)</p><p>Colon (7.1)</p><p>Esophagus (7.1)</p></td><td style="text-align: left;"><p>‐ 1.5 T</p><p>‐ SE‐EPI</p><p>‐ 500, 33, 90°</p><p>‐ 6 mm</p><p>‐ 220 × 220, 128 × 128</p><p>‐ NR</p><p>‐ Yes</p><p>‐ 0.1 mmol/kg</p><p>‐ 5 ml/s</p></td><td style="text-align: left;">Commercially available (Philips Easy Vision, Philips Healthcare)</td><td style="text-align: left;">An observer</td><td style="text-align: left;">rCBV (CBV lesion<a href="#jmri26812-note-0002" data-ref-type="fn">a</a>/CBV NACWM<a href="#jmri26812-note-0002" data-ref-type="fn">a</a>) &gt;2.1</td><td>0</td><td style="text-align: left;">MRI + clinical follow‐up (100%)</td><td style="text-align: left;">25.0</td></tr><tr class="even"><td style="text-align: left;">Hoefnagels et al<a href="#jmri26812-bib-0030" data-ref-type="ref">30</a></td><td style="text-align: left;">2009, The Netherlands</td><td style="text-align: left;">31, mean age 54,0 years (range 36‐72), 12 males</td><td style="text-align: left;"><p>Lung (58.8)</p><p>Breast (14.7)</p><p>Ovary (8.8)</p><p>Melanoma (5.9)</p><p>Renal (5.9)</p><p>Bladder (2.9)</p><p>Colon (2.9)</p></td><td style="text-align: left;"><p>‐ 1.5 T</p><p>‐ GRE‐EPI</p><p>‐ 1440, 47, 90°</p><p>‐ 5 mm</p><p>‐ 230 × 230, 128 × 128</p><p>‐ 50 measurements in 72 s</p><p>‐ NR</p><p>‐ 0.1 mmol/kg</p><p>‐ 5 ml/s</p></td><td style="text-align: left;">Commercially available (Leonardo, Siemens Healthcare)</td><td style="text-align: left;">An experienced neuroradiologist</td><td style="text-align: left;"><p>‐ Presence of nodular highly vascularized areas within the contrast‐enhancing lesion</p><p>‐ rCBV (maximum CBV lesion/mean CBV NACWM) &gt;2.0</p><p>‐ rCBV (maximum CBV lesion/mean CBV NACGM) &gt;1.85</p></td><td>0</td><td style="text-align: left;">Histopathology<a href="#jmri26812-note-0004" data-ref-type="fn">c</a> (18%) or MRI + clinical follow‐up (82%)</td><td style="text-align: left;">20/34</td></tr><tr class="odd"><td style="text-align: left;">Barajas et al<a href="#jmri26812-bib-0011" data-ref-type="ref">11</a></td><td style="text-align: left;">2009, USA</td><td style="text-align: left;">27, NR, 11 males</td><td style="text-align: left;"><p>Lung (59.3)</p><p>Breast (29.6)</p><p>Renal (7.4)</p><p>Extremity sarcoma (3.7)</p></td><td style="text-align: left;"><p>‐ 1.5 T</p><p>‐ GRE‐EPI</p><p>‐ 1000‐1250, 54, 35°</p><p>‐ NR</p><p>‐ NR</p><p>‐ 60 measurements in 75 s</p><p>‐ NR</p><p>‐ 0.1 mmol/kg</p><p>‐ 4 or 5 ml/s</p></td><td style="text-align: left;">Commercially available (Advantage Workstation, GE Healthcare).</td><td style="text-align: left;">An attending neuroradiologist</td><td style="text-align: left;">rCBV (CBV lesion<a href="#jmri26812-note-0002" data-ref-type="fn">a</a>/NACWM<a href="#jmri26812-note-0002" data-ref-type="fn">a</a>) &gt;1.52</td><td>16.7</td><td style="text-align: left;">Histopathology<a href="#jmri26812-note-0006" data-ref-type="fn">e</a> (73%) or MRI + clinical follow‐up (27%)</td><td style="text-align: left;">58.8</td></tr><tr class="even"><td style="text-align: left;">Truong et al<a href="#jmri26812-bib-0008" data-ref-type="ref">8</a></td><td style="text-align: left;">2006, USA</td><td style="text-align: left;">15, NR, NR</td><td style="text-align: left;">NR</td><td style="text-align: left;"><p>‐ NR</p><p>‐ SE‐EPI</p><p>‐ 100, 54, 90°</p><p>‐ 5 or 7 mm</p><p>‐ 230 × 230, 128 × 128</p><p>‐ 60 measurements</p><p>‐ 0.1 mmol/kg</p><p>‐ NR</p><p>‐ 5 ml/s</p></td><td style="text-align: left;">Commercially available (Unix workstation) using in‐house software</td><td style="text-align: left;">NR</td><td style="text-align: left;">rCBV (maximum CBV lesion/mean CBV NACWM) &gt;1.52</td><td>20.0</td><td style="text-align: left;">Histopathology<sup>c</sup> (100%)</td><td style="text-align: left;">83.3</td></tr></tbody></table>

GRE‐EPI: gradient echo echo‐planar imaging; NACWM: normal‐appearing contralateral white matter; NACGM: normal‐appearing contralateral gray matter; NR: not reported; rCBV: relative cerebral blood volume; SE‐EPI: spin echo echo‐planar imaging/

Percentage of lesions that were verified by this reference standard.

Not further specified.

Presence of viable tumor.

≥20% neoplastic features in the surgical specimen.

\>1% viable tumor.

Study Quality Assessment

Study quality was assessed by using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS‐2) tool, which comprises four key domains: \"patient selection,\" \"index test,\" \"reference standard,\" and \"flow and timing.\"[13](#jmri26812-bib-0013){ref-type="ref"}

*Statistical Analyses* {#jmri26812-sec-0017}
----------------------

Sensitivity and specificity of individual studies were calculated. A bivariate random‐effects model was used for meta‐analysis.[9](#jmri26812-bib-0009){ref-type="ref"} Individual studies were plotted in receiver operating characteristic (ROC) space, as were the summary estimate with 95% confidence ellipse.[14](#jmri26812-bib-0014){ref-type="ref"} A chi‐squared test was performed to test for heterogeneity. Potential sources for heterogeneity were explored by assessing whether certain covariates significantly influenced the relative diagnostic odds ratio (RDOR).[15](#jmri26812-bib-0015){ref-type="ref"} Prespecified covariates were publication year (published before vs. in or after 2013 \[2013 was the median\]), country of origin (USA vs. other countries), study size (\<28 vs. \>28 patients \[28 was the median\]), and DSC MR perfusion interpretation method (visual analysis of CBV map vs. rCBV measurement). In studies that performed both visual analysis of CBV map and rCBV measurement, we compared the area under the ROC curve (AUC) for both methods.[16](#jmri26812-bib-0016){ref-type="ref"} Potential publication bias was assessed by a funnel plot.[17](#jmri26812-bib-0017){ref-type="ref"} Statistical analyses were performed using Meta‐analysis of Diagnostic Accuracy Studies package in R software[18](#jmri26812-bib-0018){ref-type="ref"}, [19](#jmri26812-bib-0019){ref-type="ref"} and MedCalc Statistical Software, v. 15.8 (MedCalc Software, Ostend, Belgium). *P* \< 0.05 was considered statistically significant for all analyses.

Results {#jmri26812-sec-0018}
=======

*Literature Search* {#jmri26812-sec-0019}
-------------------

The study selection process is displayed in Fig. [3](#jmri26812-fig-0003){ref-type="fig"}. Fifteen studies were potentially eligible for inclusion.[8](#jmri26812-bib-0008){ref-type="ref"}, [11](#jmri26812-bib-0011){ref-type="ref"}, [20](#jmri26812-bib-0020){ref-type="ref"}, [21](#jmri26812-bib-0021){ref-type="ref"}, [22](#jmri26812-bib-0022){ref-type="ref"}, [23](#jmri26812-bib-0023){ref-type="ref"}, [24](#jmri26812-bib-0024){ref-type="ref"}, [25](#jmri26812-bib-0025){ref-type="ref"}, [26](#jmri26812-bib-0026){ref-type="ref"}, [27](#jmri26812-bib-0027){ref-type="ref"}, [28](#jmri26812-bib-0028){ref-type="ref"}, [29](#jmri26812-bib-0029){ref-type="ref"}, [30](#jmri26812-bib-0030){ref-type="ref"}, [31](#jmri26812-bib-0031){ref-type="ref"}, [32](#jmri26812-bib-0032){ref-type="ref"} After reviewing the full text, one study was excluded because the accuracy of DSC MR perfusion was not investigated[24](#jmri26812-bib-0024){ref-type="ref"}; two studies were excluded because only a change in DSC MR perfusion before and after radiotherapy as predictor of metastatic tumor response was assessed,[31](#jmri26812-bib-0031){ref-type="ref"}, [32](#jmri26812-bib-0032){ref-type="ref"} one study was excluded because it provided insufficient data for a 2 × 2 contingency table,[27](#jmri26812-bib-0027){ref-type="ref"} and one study was excluded because no separable data on the accuracy of DSC MR perfusion were reported.[25](#jmri26812-bib-0025){ref-type="ref"} Eventually, 10 studies were included.[8](#jmri26812-bib-0008){ref-type="ref"}, [11](#jmri26812-bib-0011){ref-type="ref"}, [20](#jmri26812-bib-0020){ref-type="ref"}, [21](#jmri26812-bib-0021){ref-type="ref"}, [22](#jmri26812-bib-0022){ref-type="ref"}, [23](#jmri26812-bib-0023){ref-type="ref"}, [26](#jmri26812-bib-0026){ref-type="ref"}, [28](#jmri26812-bib-0028){ref-type="ref"}, [29](#jmri26812-bib-0029){ref-type="ref"}, [30](#jmri26812-bib-0030){ref-type="ref"}

![Flowchart of the study selection process. \*All 15 potentially relevant studies were found in both databases.](JMRI-51-524-g003){#jmri26812-fig-0003}

The median number of patients per study was 28 (range 15--46). DSC MR perfusion data were available on 271 metastases. The median prevalence of recurrent brain metastases was 56.9% (range 7.7%--83.3%).

*Methodologic Quality Assessment* {#jmri26812-sec-0020}
---------------------------------

QUADAS‐2 assessments are displayed in Table [2](#jmri26812-tbl-0002){ref-type="table"} and summarized in Fig. [4](#jmri26812-fig-0004){ref-type="fig"}. Risk of bias with respect to patient selection was rated \"unclear\" in two studies[5](#jmri26812-bib-0005){ref-type="ref"}, [28](#jmri26812-bib-0028){ref-type="ref"}, [30](#jmri26812-bib-0030){ref-type="ref"} because it was unclear whether a consecutive or random sample was enrolled and whether there were no inappropriate exclusions. Risk of bias with respect to index test was rated \"high\" in seven studies[11](#jmri26812-bib-0011){ref-type="ref"}, [20](#jmri26812-bib-0020){ref-type="ref"}, [21](#jmri26812-bib-0021){ref-type="ref"}, [22](#jmri26812-bib-0022){ref-type="ref"}, [26](#jmri26812-bib-0026){ref-type="ref"}, [28](#jmri26812-bib-0028){ref-type="ref"}, [29](#jmri26812-bib-0029){ref-type="ref"} because diagnostic criteria were not prespecified. Risk of bias with respect to reference standard was rated \"unclear\" in eight studies,[8](#jmri26812-bib-0008){ref-type="ref"}, [11](#jmri26812-bib-0011){ref-type="ref"}, [20](#jmri26812-bib-0020){ref-type="ref"}, [22](#jmri26812-bib-0022){ref-type="ref"}, [23](#jmri26812-bib-0023){ref-type="ref"}, [26](#jmri26812-bib-0026){ref-type="ref"}, [28](#jmri26812-bib-0028){ref-type="ref"}, [29](#jmri26812-bib-0029){ref-type="ref"} because it was unclear whether the reference standard was interpreted without knowledge of the results of DSC MR perfusion. Risk of bias with respect to flow and timing was rated \"unclear\" in seven studies[11](#jmri26812-bib-0011){ref-type="ref"}, [20](#jmri26812-bib-0020){ref-type="ref"}, [22](#jmri26812-bib-0022){ref-type="ref"}, [23](#jmri26812-bib-0023){ref-type="ref"}, [26](#jmri26812-bib-0026){ref-type="ref"}, [28](#jmri26812-bib-0028){ref-type="ref"}, [30](#jmri26812-bib-0030){ref-type="ref"} because it was unclear whether DSC MR perfusion results influenced the decision which reference standard was used. Risk of bias with respect to flow and timing was rated \"high\" in one study,[8](#jmri26812-bib-0008){ref-type="ref"} because not all patients were included in the analysis. In two studies,[22](#jmri26812-bib-0022){ref-type="ref"}, [23](#jmri26812-bib-0023){ref-type="ref"} there were applicability concerns with respect to patient selection, because both stable and progressive metastases at conventional MR (contrast‐enhanced T~1~‐weighted MR images) were included. There were no other applicability concerns.

###### 

QUADAS‐2 Assessment Results of Each of the Included Studies

  Study                                                       Risk of bias   Applicability concerns                                    
  ----------------------------------------------------------- -------------- ------------------------ --------- --------- ------ ----- -----
  Wang et al[20](#jmri26812-bib-0020){ref-type="ref"}         Low            High                     Unclear   Unclear   Low    Low   Low
  Knitter et al[21](#jmri26812-bib-0021){ref-type="ref"}      Low            High                     Low       Low       Low    Low   Low
  Muto et al[22](#jmri26812-bib-0022){ref-type="ref"}         Low            High                     Unclear   Unclear   High   Low   Low
  Kerkhof al.[23](#jmri26812-bib-0023){ref-type="ref"}        Low            Unclear                  Unclear   Unclear   High   Low   Low
  Cicone et al[26](#jmri26812-bib-0026){ref-type="ref"}       Low            High                     Unclear   Unclear   Low    Low   Low
  Huang et al[28](#jmri26812-bib-0028){ref-type="ref"}        Low            High                     Unclear   Unclear   Low    Low   Low
  Mitsuya et al[29](#jmri26812-bib-0029){ref-type="ref"}      Low            High                     Unclear   Low       Low    Low   Low
  Hoefnagels et al[30](#jmri26812-bib-0030){ref-type="ref"}   Unclear        Low                      Low       Unclear   Low    Low   Low
  Barajas et al[11](#jmri26812-bib-0011){ref-type="ref"}      Low            High                     Unclear   Unclear   Low    Low   Low
  Truong et al[8](#jmri26812-bib-0008){ref-type="ref"}        Unclear        Unclear                  Unclear   High      Low    Low   Low

![Summary of QUADAS‐2 assessments of the 10 included studies.](JMRI-51-524-g004){#jmri26812-fig-0004}

![Forest plots of sensitivity and specificity of included studies. ^a^absolute CBV; ^b^rCBV; ^c^At 3 months follow‐up; ^d^At 6 months follow‐up; ^e^Subjective scoring of CBV map; ^f^rCBV (maximum CBV lesion/mean CBV NACWM); ^g^rCBV (maximum CBV lesion/mean CBV NACGM).](JMRI-51-524-g005){#jmri26812-fig-0005}

*Diagnostic Performance* {#jmri26812-sec-0021}
------------------------

Different diagnostic criteria were used (Table [1](#jmri26812-tbl-0001){ref-type="table"}). Both sensitivity and specificity from individual studies ranged from 0% to 100% (Fig. [5](#jmri26812-fig-0005){ref-type="fig"}), with pooled estimates of 81.6% (95% confidence interval \[CI\]: 70.6%, 89.1%) and 80.6% (95% CI: 64.2%, 90.6%), respectively. The ROC plot is shown in Fig. [6](#jmri26812-fig-0006){ref-type="fig"}. The AUC was 0.873. All studies, except Muto et al\'s study,[22](#jmri26812-bib-0022){ref-type="ref"} reported accuracy data on a per‐lesion basis. Muto et al\'s study[22](#jmri26812-bib-0022){ref-type="ref"} used number of MR examinations (mean of 2.69 per patient) for accuracy analysis. Excluding this study[22](#jmri26812-bib-0022){ref-type="ref"} from meta‐analysis resulted in pooled sensitivity of 79.4% (95% CI: 68.6%, 87.2%) and pooled specificity of 77.3% (95% CI: 61.6%, 87.9%), with an AUC of 0.847.

![Receiver operating characteristic plot. \*Individual study data (small triangles) have been plotted in ROC space, as were the summary estimate (small circle) with 95% confidence ellipse (oval area, thin line) and summary receiver operating characteristic curve (thick line). \*From Wang et al\'s study,[20](#jmri26812-bib-0020){ref-type="ref"} rCBV data were used; from Kerkhof et al\'s study,[23](#jmri26812-bib-0023){ref-type="ref"} 3‐month follow‐up data were used; and from Hoefnagels et al\'s study,[30](#jmri26812-bib-0030){ref-type="ref"} data from visual CBV map analysis were used for analysis. SROC: summary receiver operating characteristic curve; conf. region: 95% confidence ellipse of pooled sensitivity and specificity.](JMRI-51-524-g006){#jmri26812-fig-0006}

The median percentage of uninterpretable lesions per study was 5.35 (range 0--20.0) (Table [1](#jmri26812-tbl-0001){ref-type="table"}). In one study,[30](#jmri26812-bib-0030){ref-type="ref"} six lesions were excluded from accuracy analysis because visual CBV map analysis was nonconclusive.

The included studies were heterogeneous in sensitivity (*P* = 0.005) and specificity (*P* \< 0.001). RDORs were not significantly different in subgroups according to publication year, country of origin, study size, and DSC MR perfusion interpretation method (Table [3](#jmri26812-tbl-0003){ref-type="table"}). In the only included study that performed both visual analysis of the CBV map and rCBV measurement,[30](#jmri26812-bib-0030){ref-type="ref"} AUCs did not significantly differ: AUC of 0.813 (95% CI: 0.621, 0.934) for visual analysis of CBV map vs. AUC of 0.754 (95% CI, 0.556, 0.896) for rCBV measurement (*P* = 0.6167).

###### 

Subgroup Analyses

  Parameter                                Variables[a](#jmri26812-note-0007){ref-type="fn"}            Relative diagnostic odds ratio[b](#jmri26812-note-0008){ref-type="fn"}   *P* value
  ---------------------------------------- ------------------------------------------------------------ ------------------------------------------------------------------------ -----------
  Publication year                         Published after (5) vs. published before 2013 (5)            2.21 (0.14, 34.01)                                                       0.5157
  Country of origin                        USA (6) vs. Other countries (4)                              0.21 (0.01, 2.92)                                                        0.2030
  Study size                               \>28 patients (5) vs. \<28 (5)                               1.88 (0.11, 31.20)                                                       0.6101
  DSC MR perfusion interpretation method   Visual analysis of CBV map (2) vs. measurement of rCBV (7)   0.22 (0.01, 8.93)                                                        0.3554

Data in parentheses are number of studies.

Data in parentheses are 95% CIs.

The funnel plot (Fig. [7](#jmri26812-fig-0007){ref-type="fig"}) was roughly symmetrical, suggesting a low likelihood of publication bias.

![Funnel plot using the diagnostic odds ratio of the 10 included studies. \*Two diagonal lines represent 95% confidence limits (effect ±1.96 standard error) around the summary effect (vertical line) for each standard error on the vertical axis.](JMRI-51-524-g007){#jmri26812-fig-0007}

Discussion {#jmri26812-sec-0022}
==========

This systematic review investigated the accuracy of DSC MR perfusion in diagnosing recurrent brain metastases after radiotherapy. Different diagnostic criteria were used by the included studies to define metastatic recurrence. We used a bivariate random‐effects model for meta‐analysis, which acknowledges a possible threshold effect.[14](#jmri26812-bib-0014){ref-type="ref"} Pooled sensitivity and specificity were fairly high, but there was significant between‐study heterogeneity.

Potential bias in the domains \"index test,\" \"reference standard,\" and \"flow and timing\" may have resulted in overestimation of accuracy. In clinical practice, DSC MR perfusion is typically used to differentiate treatment‐related changes from recurrence in irradiated metastases which show a new area of enhancement and/or enlargement at conventional MR. There were applicability concerns with respect to patient selection in two studies,[22](#jmri26812-bib-0022){ref-type="ref"}, [23](#jmri26812-bib-0023){ref-type="ref"} because they included both stable and progressive metastases at conventional MR. However, DSC MR perfusion may also have value in metastases that show stability or regression at conventional MR, because changes in tumor physiology may precede structural changes.

DSC MR perfusion can be performed on any modern MR scanner, has a short acquisition time, and postprocessing software is widely available.[33](#jmri26812-bib-0033){ref-type="ref"} However, it has some inherent limitations. Blood products or melanin within brain metastases can cause a significant degree of susceptibility artifacts, impeding assessment.[11](#jmri26812-bib-0011){ref-type="ref"}, [23](#jmri26812-bib-0023){ref-type="ref"} Furthermore, metastases may not be evaluable if they are too small or near large vessels or bone.[23](#jmri26812-bib-0023){ref-type="ref"} In this systematic review, the median percentage of uninterpretable lesions was 5.35%.

The studies that measured rCBV showed variation in region of interest (ROI) placement: ROIs were placed encompassing the entire contrast‐enhancing lesion[21](#jmri26812-bib-0021){ref-type="ref"}, [22](#jmri26812-bib-0022){ref-type="ref"}, [26](#jmri26812-bib-0026){ref-type="ref"} or in selected areas of the contrast‐enhancing lesion,[8](#jmri26812-bib-0008){ref-type="ref"}, [11](#jmri26812-bib-0011){ref-type="ref"}, [20](#jmri26812-bib-0020){ref-type="ref"}, [29](#jmri26812-bib-0029){ref-type="ref"} whereas in some studies the method of ROI placement was not described.[28](#jmri26812-bib-0028){ref-type="ref"}, [30](#jmri26812-bib-0030){ref-type="ref"} Some studies measured mean values, whereas other studies measured maximum values. The mean value varies depending on which voxels are included in the average, making it sensitive to ROI definition. The maximum value is less dependent on ROI definition (assuming the voxel with highest CBV and no normal macrovessels are included) but more susceptible to noise. Only two of the included studies reported interobserver reproducibility.[20](#jmri26812-bib-0020){ref-type="ref"}, [22](#jmri26812-bib-0022){ref-type="ref"} Wang et al[20](#jmri26812-bib-0020){ref-type="ref"} reported good interobserver agreement for mean rCBV. Muto et al[22](#jmri26812-bib-0022){ref-type="ref"} also reported good interobserver agreement, but did not specify whether this applied to mean or maximum rCBV. Furthermore, it has recently been shown that ROI placement in the semioval center as reference tissue provides the highest interobserver agreement.[34](#jmri26812-bib-0034){ref-type="ref"} However, only one of the included studies reported using the semioval center as reference tissue.[30](#jmri26812-bib-0030){ref-type="ref"} One other study used the normal‐appearing contralateral white matter (NACWM) on the same transaxial plane as the lesion as reference tissue,[11](#jmri26812-bib-0011){ref-type="ref"} whereas in the other studies[8](#jmri26812-bib-0008){ref-type="ref"}, [20](#jmri26812-bib-0020){ref-type="ref"}, [21](#jmri26812-bib-0021){ref-type="ref"}, [22](#jmri26812-bib-0022){ref-type="ref"}, [26](#jmri26812-bib-0026){ref-type="ref"}, [28](#jmri26812-bib-0028){ref-type="ref"}, [29](#jmri26812-bib-0029){ref-type="ref"} the exact location of ROI placement in the NACWM was not reported.

Exploratory subgroup analyses suggested that publication year, country of origin, study size, and DSC MR perfusion interpretation methods were no causes of heterogeneity. ROC curve analysis of the only included study that performed both visual analysis of CBV map and rCBV measurement[30](#jmri26812-bib-0030){ref-type="ref"} also showed that diagnostic accuracy between both perfusion interpretation methods was not significantly different. Pretreatment rCBV of brain metastases from renal carcinoma and melanoma are significantly higher than rCBV of brain metastases from lung, breast, and gastrointestinal carcinoma.[35](#jmri26812-bib-0035){ref-type="ref"}, [36](#jmri26812-bib-0036){ref-type="ref"} Furthermore, it has been shown by microscopy that neovascularization patterns of brain metastases from a different origin can be quite different. For instance, neovascularization is a specific hallmark of nonsmall‐cell lung cancer metastases, whereas melanoma metastases show less neovascularization and more perivascular growth along preexisting vascular structures.[37](#jmri26812-bib-0037){ref-type="ref"} Therefore, one may expect that the diagnostic performance of DSC MR perfusion differs considerably among different tumor entities. However, all included studies pooled metastases of different primary tumor origin together, so it was not possible to investigate the influence of primary tumor origin on accuracy. Another potential source of heterogeneity is the use of different definitions for recurrent metastases in studies using histopathology as the reference standard. Other potential sources of heterogeneity are variations in MR parameters (such as the use of preload, leakage correction, injection rate, flip angle, and temporal coverage), postprocessing methods (for leakage correction), and diagnostic criteria. Unfortunately, due to large variability between studies, we could not perform meaningful subgroup analyses for these parameters.

This systematic review has some limitations. First, the number of included studies was relatively low. Therefore, we could not fully explore potential sources of heterogeneity with subgroup analysis or meta‐regression. Second, the funnel plot which suggested the absence of publication bias is not always a reliable tool.[38](#jmri26812-bib-0038){ref-type="ref"}, [39](#jmri26812-bib-0039){ref-type="ref"}

Conventional MRI findings of treatment‐related changes and metastatic recurrence overlap considerably.[4](#jmri26812-bib-0004){ref-type="ref"}, [5](#jmri26812-bib-0005){ref-type="ref"}, [6](#jmri26812-bib-0006){ref-type="ref"} Therefore, DSC MR perfusion can be a very useful adjunct in diagnosing recurrent brain metastases after radiotherapy. However, pooled sensitivity and specificity of DSC MR perfusion were fairly high, but not perfect. Furthermore, it is still questionable whether these pooled overall results can be applied to all metastases of different primary origin and there is no uniformly accepted diagnostic criterion yet. Therefore, one should be careful to make clinical decisions based on DSC MR perfusion results alone. The question remains as to what represents \"best practice\" based on current evidence. We suggest that DSC MR perfusion acquisitions are performed according to recommendations from the American Society of Functional Neuroradiology (ASFNR).[12](#jmri26812-bib-0012){ref-type="ref"} According to the ASFNR, preload administration of a single contrast agent bolus with postprocessing leakage correction and implicit correction of T~1~ leakage effects with a dual‐echo acquisition methodology are the two methods that best distinguish rCBV in tumor from normal brain in the presence of contrast agent leakage effects.[12](#jmri26812-bib-0012){ref-type="ref"} We suggest that either one of these methods is used. We found no evidence that either visual analysis of CBV maps or rCBV measurements performed better than the other in terms of diagnostic accuracy. Therefore, at present it may be justified to use either one of these perfusion interpretation methods. We believe that all MRI results should be interpreted in the clinical context (including patient symptoms and clinical findings, date and type of treatment received, and systemic status). This is preferably discussed in a neuro‐oncology multidisciplinary team meeting, which is the optimal place to make decisions regarding further diagnostic work‐up (such as closer follow‐up or stereotactic biopsy) and treatment.[40](#jmri26812-bib-0040){ref-type="ref"}, [41](#jmri26812-bib-0041){ref-type="ref"}

In order to validate DSC MR perfusion for clinical application, it is essential to further investigate potential causes of heterogeneity. Ideally, this is done by prospective studies following ASFNR recommendations regarding DSC MR perfusion acquisition and postprocessing. Future studies should make a direct comparison between DSC MR perfusion interpretation methods and perform stratified analysis for metastases per primary tumor type. Diagnostic accuracy may be improved by combining DSC MR perfusion with other advanced MR techniques[25](#jmri26812-bib-0025){ref-type="ref"} or positron emission tomography,[42](#jmri26812-bib-0042){ref-type="ref"}, [43](#jmri26812-bib-0043){ref-type="ref"} but this also needs further investigation.

In conclusion, the results of our study suggest that the accuracy of DSC MR perfusion in diagnosing recurrent brain metastases after radiotherapy is fairly high. However, these findings should be interpreted with caution because of methodological quality concerns and heterogeneity between studies. There is no uniformly accepted diagnostic criterion to define metastatic recurrence yet. Potential causes of heterogeneity need to be further investigated.
